Technology ID
TAB-3519
Remodelins, a New Class of Compounds to Prevent or Treat Cancer Metastasis or Glaucoma
E-Numbers
E-179-2018-0
Lead Inventor
Luci, Diane
Lead IC
NCATS
Co-Inventors
Solway, Julian
Park, ChanYoung
Fredberg, Jeffery
McCormick, David
Maloney, David
Dulin, Nickolai
Krishnan, Ramaswamy
Chen, Bohao
Wang, Jiaolong
Lavoie, Tera
Gurvich, Vadim
Byrn, Stephen
Muzzio, Miguel
White, Stephen
Laxman, Bharathi
He, Tong-Chuan
Conzen, Suzanne
Rosner, Marsha
ICs
NCATS
Applications
Therapeutics
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
This technology includes a series of small molecule organic compounds, called remodelins, that are synthetic derivative analogs of a parent compound discovered by screening of a Chembridge library. The novel synthetic derivative analogs were generated through multiple iterations of compounds directed by in vitro experiments. The invention also includes use of these or related molecules to treat cancer and/or glaucoma.
Commercial Applications
Further clinical work with the remodelins could establish these compounds for the inhibition or treatment of cancer metastasis and/or glaucoma.
Competitive Advantages
This invention is a new class of compounds for the treatment of cancer and/or glaucoma.
Licensing Contact: